-
1 Comment
Cleveland BioLabs, Inc is currently in a long term uptrend where the price is trading 5.3% above its 200 day moving average.
From a valuation standpoint, the stock is 78.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 294.7.
Cleveland BioLabs, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 1.8% to $-695K since the same quarter in the previous year.
Finally, its free cash flow fell by 115.4% to $-788K since the same quarter in the previous year.
Based on the above factors, Cleveland BioLabs, Inc gets an overall score of 3/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US8575611046 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 49M |
|---|---|
| PE Ratio | None |
| Target Price | 2 |
| Dividend Yield | 0.0% |
| Beta | 0.68 |
Cytocom, Inc., a clinical-stage biopharmaceutical company, develops novel small molecule immunotherapies targeting cancer, autoimmune, inflammatory, and infectious diseases. Its platform, Advanced Immunomodulating Multi-receptor System (AIMS), offers noroxymorphone analogs multi-receptor modulating therapies and proenkephalin analogs multi-receptor modulating therapies. The company also has various clinical-stage development programs, including CYTO-200 for Crohn's disease, fibromyalgia, multiple sclerosis, and covid-19; CYTO-400 for hepatocellular and pancreatic cancer; and CYTO-600 for acute radiation syndrome, advanced solid tumors, and vaccine adjuvant. Cytocom, Inc. has a collaboration agreement with the La Jolla Institute for Immunology for research and development of new immune-modulating agents targeting toll-like receptors for the treatment of cancer, infectious, autoimmune, and chronic inflammatory diseases. The company is based in Fort Collins, Colorado.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CBLI using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
